European Regulators Ready to Review Emmaus’s Sickle Cell Disease Therapy
The European Medicines Agency (EMA) has signaled that it is ready to begin reviewing Emmaus Life Sciences’ Xyndari as a possible treatment for sickle cell disease (SCD). The signal was the ... Read more